Vedolizumab

Vedolizumab is a monoclonal antibody being developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease.^[1] It binds to integrin α₄β₇ (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1)^[1]^[2]

As of October 2009^[update], vedolizumab is undergoing Phase III trials.^[3]

References

^ ^a ^b Statement On A Nonproprietary Name Adopted By The USAN Council - Vedolizumab, American Medical Association.
^ Soler, D; Chapman, T; Yang, LL; Wyant, T; Egan, R; Fedyk, ER (2009). "The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases". The Journal of pharmacology and experimental therapeutics 330 (3): 864–75. doi:10.1124/jpet.109.153973. PMID 19509315.
^ ClinicalTrials.gov NCT00790933 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease (GEMINI II)

Immune system ("-l(i[m])-")

Human ("-limu-")	immunosuppression: Adalimumab • Atorolimumab • Brodalumab • Carlumab • Fresolimumab • Golimumab • Lerdelimumab • Mavrilimumab • Metelimumab • Morolimumab • Namilumab • Oxelumab • Sarilumab • Sifalimumab • Tabalumab • Urelumab immune activation: Ipilimumab • Tremelimumab other: Bertilimumab • Zanolimumab

Mouse ("-limo-")	Afelimomab • Elsilimomab • Faralimomab • Gavilimomab • Inolimomab • Maslimomab • Nerelimomab • Odulimomab • Telimomab aritox • Vepalimomab • Zolimomab aritox

Chimeric ("-lixi-")	Basiliximab • Clenoliximab • Galiximab • Gomiliximab • Infliximab • Keliximab • Lumiliximab • Priliximab • Teneliximab • Vapaliximab

Humanized ("-lizu-")	immunosuppressive: Aselizumab • Apolizumab • Benralizumab^† • Cedelizumab • Certolizumab pegol • Daclizumab • Eculizumab • Efalizumab • Epratuzumab • Erlizumab • Etrolizumab • Fontolizumab • Itolizumab • Mepolizumab • Mogamulizumab • Natalizumab • Ocrelizumab • Omalizumab • Ozoralizumab • Pascolizumab • Pateclizumab • Pexelizumab • PRO 140^† • Reslizumab • Rontalizumab • Rovelizumab • Ruplizumab • Samalizumab • Siplizumab • Talizumab • Teplizumab • Tocilizumab • Toralizumab • Tregalizumab • Vatelizumab • Vedolizumab • Visilizumab • TGN1412^§ non-immunosuppressive: Ibalizumab^†

Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Briakinumab • Canakinumab • Fezakinumab • Secukinumab • Sirukumab • Tralokinumab • Ustekinumab

Humanized ("-kizu-", "-kinzu-")	Anrukinzumab • Enokizumab • Gevokizumab • Ixekizumab • Lebrikizumab • Olokizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab • Fanolesomab^‡ • Lemalesomab • Sulesomab

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)